Colinz Laboratories Limited recently concluded a significant postal ballot process, resulting in the approval of two special resolutions by its shareholders. The e-voting, which took place from October 15 to November 14, 2025, focused on the company's plans to sell, lease, mortgage, or dispose of key properties.

Resolutions Passed

The shareholders voted on two important resolutions:

1. The sale, lease, mortgage, or disposal of the company's factory located in Sinnar, Nashik.
2. Similar actions for the company's office in Mumbai.

Voting Results

The outcome of the postal ballot demonstrated strong shareholder support for both resolutions:

The overwhelming majority in favor of these resolutions indicates significant shareholder alignment with the company's strategic decisions regarding its property assets.

Implications

The approval of these resolutions grants Colinz Laboratories the flexibility to make strategic decisions regarding its properties in Nashik and Mumbai. This could potentially impact the company's operational footprint and financial structure, depending on how the management chooses to proceed with these newly approved options.

Shareholders and market observers may want to keep an eye on future announcements from Colinz Laboratories regarding the execution of these approved actions and their potential impact on the company's operations and financial position.

As the company moves forward with these approvals, it may lead to changes in its asset structure, potentially affecting its balance sheet and operational capabilities. However, the specific plans and timeline for implementing these resolutions have not been disclosed in the current announcement.

Colinz Laboratories , a pharmaceutical company, has announced significant changes to its board of directors and committee structure, following the passing of a key board member.

Board Changes

The company reported the sad demise of Dr. Mani L.S., who served as a Non-Executive Director. The board expressed deep condolences, acknowledging Dr. Mani's visionary leadership, unwavering commitment, and exemplary guidance that left an indelible mark on the company.

In light of this loss, Colinz Laboratories has appointed Mrs. Vijaya Mani as an Additional Non-Executive Director, effective November 11, 2025. This appointment is subject to shareholder approval at the forthcoming Annual General Meeting.

New Director Profile

Mrs. Vijaya Mani brings a diverse background to the board:

• Educational Background: BA Graduate
• Experience: Extensive experience in Admin and Banking
• Industry Knowledge: Well-versed with pharmaceutical background

The company believes Mrs. Mani's expertise will contribute to its growth and future success.

Committee Restructuring

Following these changes, Colinz Laboratories has reconstituted its board committees. The new structure is as follows:

Regulatory Compliance

Colinz Laboratories has confirmed that Mrs. Vijaya Mani has not been debarred from holding the office of director by any SEBI order or any other authority. This appointment and the subsequent committee restructuring comply with the relevant SEBI regulations and the Companies Act, 2013.

The company's board meeting, where these decisions were made, commenced at 03:30 p.m. and concluded at 5:00 p.m. on November 11, 2025.

These changes mark a significant transition for Colinz Laboratories as it adapts its leadership structure to navigate future challenges and opportunities in the pharmaceutical industry.